应用有害结局路径思维把关乳制品雌激素安全  

Application of adverse outcome pathway concept to ensure estrogen safety in dairy products

作　　者：陈雪平 宋晓丹 

机构地区：[1]水中银(国际)生物科技有限公司(香港),香港999077 [2]圣元营养食品有限公司北京营养研究院,北京100020

出　　处：《中国乳品工业》2017年第12期34-36,共3页China Dairy Industry

摘　　要：以Choriogenin H-green fluorescent protein(Chg H-GFP)转基因鲭鳉鱼自由胚胎测试乳制品的总体生物雌激素活性水平为例,首次提出并阐述应用"有害结局路径(adverse outcome pathway,AOP)"思维来评估乳制品雌激素安全的理论和建议。The estrogen safety issue has been a change to the dairy industry for a long time. Estrogens in dairy products are generally classi- fied as endogenous and exogenous estrogens. Although there are controversial opinions concerning the safety impact of endogenous estro- gens. It is generally agreed that exogenous estrogens should be of more concerns. By using choriogenin H-green fluorescent protein （Ch- gH-GFP） transgenic medaka eleutheroembryo based total biological estrogenic activity test as an example this paper proposes and argues to apply the concept of ＂adverse outcome pathway （AOP）＂ to estrogen safety evaluation of dairy products.

关 键 词：有害结局路径 乳制品 转基因鱼 雌激素当量 

分 类 号：TS201.6[轻工技术与工程—食品科学]